肝细胞生长因子水平与冠状动脉粥样硬化及高血压病的关系被引量：4

Relationship between the levels of serum hepatocyte growth factor and coronary atherosclerosis and clinical severity of essential hypertension

暂未订购

导出

摘要目的 :探讨血清肝细胞生长因子 (HGF)水平与冠状动脉粥样硬化 (CAS)及高血压病程、病期的关系。方法 :将 44例原发性高血压 (EH)患者分成单纯 EH组和 EH+CAS组 ,用酶联免疫吸附法 (EL ISA)测定其血清 HGF水平。结果 :单纯 EH组 HGF水平 [(747.9± 132 .1) pg/ml]比正常人 [(6 43.8± 98.2 ) pg/ml]高 ,而 EH +CAS组 HGF水平 [(92 0 .8± 2 5 0 .0 )pg/m l]则明显高于正常对照组和单纯 EH组 (P <0 .0 1) ,且 HGF水平与高血压病程长短 (r=0 .6 3,P<0 .0 1)及病期 (r=0 .6 9,P<0 .0 1)密切相关。结论 :血清 HGF升高与高血压的病程、病期及 CAS有关。 Objective: To investigate the relationship between serum HGF levels and clinical severity of essential hypertension (EH). Methods: The serum HGF concentrations of 44 patients with EH were measured by ELISA. Results: The serum HGF levels in patients with EH were higher than that in control. Furthermore, the serum HGF levels of EH patients with coronary atherosclerosis (CAS) were significantly higher than those of EH patients without CAS [(920.8±250.0) pg/ml vs (747.9±132.1) pg/ml, P <0.01] or control [(643.8±98.2) pg/ml, P <0.01)].The changes of HGF level were correlated with the clinical courses ( r =0.63, P <0.01) and stages ( r =0.69, P <0.01) of hypertension. Conclusion: HGF may be considered as a new index for the severity of hypertension and an useful biochemical parameter for estimating the development of atherosclerosis. [

作者王咏梅吴宗贵黄佐赵君陈金明殷仁富钱建英陈懿

机构地区第二军医大学长征医院心血管内科

出处《第二军医大学学报》 CAS CSCD 北大核心 2001年第2期138-139,共2页 Academic Journal of Second Military Medical University

基金上海市医学科技发展基金重大课题项目!(2 0 0 0 IZD0 0 2 )

关键词肝细胞生长因子高血压冠状动脉粥样硬化 hepatocyte growth factor hypertension atherosclerosis

分类号 R541.402 [医药卫生—心血管疾病] R544.102 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献7

1[1]Nakam ura Y, Morishita R, Higaki J, et al. Expression of local hepatocyte growth factor system in vascular tissues [J]. Biochem Biophys Res Commun, 1995, 215 (2): 483-488.
2[2]Morishita R, Moriguchi A, Higaki J, et al. Hepatocyte growth fact or (HGF) as a potential index of severity of hypertension [J]. Hypertens Res, 1999, 22(3): 161-167.
3[3]Nishimura M, Ushiyama M, Ohtsuka K, et al . Serum hepatocyte growth factor as a possible indicator of vascular lesions[ J]. J Clin Endocrinol Metab, 1999, 84(7): 2475-2480.
4[4]Nakamura T, Nawa K, Ichihara A, et al. Partial purification and c haracterization of hepatocyte growth factor from serum hepatectomized rats [J ]. Biochem Biophys Res Commun, 1984, 122(3): 1450-1459.
5[5]Nakamura T. Structure and function of hepatocyte growth factor [J ]. Prog Growth Factor Res, 1991, 3(1): 67-86.
6[6]Sato T, Yoshinouchi T, Sugimoto T, et al. Prognostic value of ser um hepatocyte growth factor in patients with acute coronary syndromes [J] . Jpn Circ J, 1999, 63(8): 583-588.
7[7]Nakamura Y, Morishita R, Nakamura S, et al. A vascular modulator, hepatocyte growth factor, is associated with systolic blood pressure [J]. Hy pertension, 1996, 28(3): 409-413.